Frazier Life Sciences Management’s Silence Therapeutics SLN Stock Holding History

Frazier Life Sciences Management’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-970,130	Closed	-$5.03M	–	51
2025 Q3	$5.03M	Hold	970,130	–	–	0.15%	45
2025 Q2	$5.63M	Sell	970,130 -178,461	-16%	-$765K	0.23%	44
2025 Q1	$3.24M	Hold	1,148,591	–	–	0.15%	46
2024 Q4	$7.9M	Hold	1,148,591	–	–	0.33%	39
2024 Q3	$20.9M	Hold	1,148,591	–	–	0.84%	27
2024 Q2	$21.8M	Hold	1,148,591	–	–	1.02%	27
2024 Q1	$24.8M	Buy	1,148,591 +267,418	+30%	+$5.81M	1.05%	28
2023 Q4	$15.3M	Hold	881,173	–	–	0.82%	34
2023 Q3	$8.66M	Hold	881,173	–	–	0.58%	33
2023 Q2	$4.85M	Hold	881,173	–	–	0.29%	42
2023 Q1	$5.46M	Hold	881,173	–	–	0.4%	41
2022 Q4	$13.4M	Hold	881,173	–	–	0.84%	24
2022 Q3	$8.7M	Hold	881,173	–	–	0.67%	32
2022 Q2	$10.4M	Hold	881,173	–	–	0.99%	28
2022 Q1	$16.7M	Buy	+881,173	New	+$17.6M	1.43%	22

Other funds holding SLN

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Frazier Life Sciences Management's SLN Position: Q4 2025 in Review

Frazier Life Sciences Management sold out of Silence Therapeutics (SLN) in Q4 2025, closing a stake of 970,130 shares — an estimated $5.03M sold.

Frazier Life Sciences Management first reported a position in SLN in Q1 2022 and held it in 15 quarters. The position peaked at $24.8M in Q1 2024. 58 funds tracked by Wall St. Rank hold SLN as of Q4 2025.

Frazier Life Sciences Management reported no remaining Silence Therapeutics position as of Q4 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 970,130 Silence Therapeutics shares in Q4 2025, an estimated $5.03M.
Frazier Life Sciences Management first reported a position in Silence Therapeutics in Q1 2022 and held it in 15 quarters.
Frazier Life Sciences Management's Silence Therapeutics position peaked at $24.8M in Q1 2024.
58 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2025.

Based on Frazier Life Sciences Management's 13F filing for Q4 2025, filed 13 Feb 2026.